The purpose of this study was to determine the effect of retroperitoneal (RP) exploration on progression-free survival (PFS) and overall survival (OS) in epithelial ovarian cancer (EOC) patients with stage IIIC disease who underwent optimal debulking surgery. METHODS: Data were collected from records of the Gynecologic Oncology Group 182 (GOG-182) study of stage IIIC EOC patients cytoreduced to no gross residual disease (R0) or minimal gross residual (<1 cm) disease (MGRD) at primary surgery. Patients with stage IIIC disease by intraperitoneal (IP) tumor were included and divided into 3 groups: 1) > 2 cm IP tumor without lymph node involvement (IP/RP2), 2) > 2 cm IP tumor with lymph node involvement (IP/RP1), and 3) > 2 cm IP tumor with no RP exploration (IP/ RP?). The effects of disease distribution and RP exploration on PFS and OS were assessed using Kaplan-Meier and proportional hazards methods. RESULTS: There were 1871 stage IIIC patients in GOG-182 who underwent optimal primary debulking surgery. Of these, 689 (36.8%) underwent RP exploration with removal of lymph nodes from at least 1 para-aortic site, and 1182 (63.2%) did not. There were 269 patients in the IP/RP2 group, 420 patients in the IP/RP 1 group, and 1182 patients in the IP/RP? group. Improved PFS (18.5 vs 16.0 months; P <.0001) and OS (53.3 vs 42.8 months; P <.0001) were associated with RP exploration versus no exploration. Patients with MGRD had improved PFS (16.8 vs 15.1 months, P 5 0.0108) and OS (44.9 vs 40.5 months, P 5 0.0076) versus no exploration. CONCLUSIONS: RP exploration at the time of primary surgery in patients with optimally debulked stage IIIC EOC is associated with a survival benefit. Cancer 2017;123:985-93.
INTRODUCTION
Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy. 1 Presence of lymph node metastases is an important prognostic factor in EOC, and the International Federation of Gynecology and Obstetrics (FIGO) staging system for ovarian cancer has included lymph node status since 1986. [2] [3] [4] [5] [6] [7] According to the previous FIGO staging system, lymph node metastasis was considered stage IIIC disease even if the primary tumor was confined to the ovary or pelvis. 6 As a result, approximately 10% to 25% of patients with presumed early stage disease confined to the ovaries or pelvis have been upgraded to stage III disease due to retroperitoneal (RP) lymph node metastasis identified during thorough surgical staging. [8] [9] [10] Although RP and intraperitoneal (IP) disease burden are both prognostically important, patients with advanced stage disease by positive lymph nodes alone have improved survival compared with those with bulky peritoneal disease. [2] [3] [4] [5] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] It is unclear whether performing an RP exploration or dissection at the time of primary cytoreductive surgery impacts survival in stage IIIC patients with IP disease. Lymph node assessment is not always performed at the time of primary debulking surgery, particularly if the patient meets other criteria for stage IIIC disease. This surgical practice has been based on data showing no survival advantage in performing lymph node assessment. In a large randomized trial comparing systematic lymphadenectomy and selective resection of only bulky lymph nodes, systematic lymphadenectomy was associated with improved PFS but not OS in optimally debulked ovarian cancer. Of the 427 patients in this trial, 75% had stage IIIC disease, but only 39% received adjuvant platinum and taxane-based chemotherapy. 23 Two additional ongoing randomized trials are currently being conducted to answer this question.
In the current absence of updated randomized data, our objective was to determine the effect of retroperitoneal exploration, defined as removal of nodal tissue from at least one pelvic or para-aortic lymph node site, on the PFS and OS in EOC patients with stage IIIC disease who underwent optimal debulking surgery in a large multiinstitutional trial. 24 
PATIENTS AND METHODS
All patient data for this study were abstracted from Gynecologic Oncology Group 182 (GOG-182), a large, multi-institutional clinical trial. 24 All GOG-182 patients were diagnosed with FIGO stage III or IV histologically confirmed EOC or primary peritoneal cancer (PPC). All patients underwent primary cytoreductive surgery to either optimal (1 cm) or suboptimal residual disease before being randomized to 1 of 5 platinum and paclitaxelbased chemotherapy regimens. No statistically significant treatment effects on PFS or OS were found. Further details of eligibility criteria and results from the original study have been published. 24 GOG-182 was activated in January 2001 and closed in September 2004.
This current study focused on those GOG-182 patients who had FIGO stage IIIC and underwent cytoreductive surgery with <1 cm residual disease. Stage IIIC patients who underwent surgical cytoreduction to no gross residual disease (R0) or minimal gross residual disease (MGRD) of 1 cm at primary debulking surgery were divided into groups based on whether a RP exploration was performed and by distribution of disease. RP exploration was defined as removal of nodal tissue from at least one pelvic or para-aortic lymph node site, as defined by the GOG Surgical Procedures Manual. 25 GOG defines pelvic lymphadenectomy as removal of nodal tissue from the distal half of the common iliac arteries, the anterior and medial aspect of the proximal half of the external iliac artery and vein, and the distal half of the obturator fat pad anterior to the obturator nerve. Para-aortic lymph node dissection is described as removal of nodal tissue over the distal inferior vena cava from the level of the inferior mesenteric artery to the mid-right common iliac artery and removal of the nodal tissue between the aorta and left ureter from the mid-inferior mesenteric artery to the mid-left common iliac artery. An adequate nodal resection requires that lymphatic tissue be excised pathologically from each side (right and left), but no specific nodal counts are required. 25 Thus, some practitioners may have opted for selective lymph node sampling rather than a full dissection.
Those patients who were stage IIIC by RP disease with positive lymph nodes only were excluded. By definition, these patients had <2 cm of IP disease outside of the pelvis and are now considered as having stage IIIA disease based on 2014 FIGO staging. 22 Those patients with stage IIIC disease with 2 cm of IP tumor were included and divided into groups based on whether an RP exploration was performed. The RP exploration group included patients with 2 cm of IP tumor with negative lymph nodes (the IP/RP2 group) and patients with 2 cm of IP tumor with positive lymph nodes (the IP/RP 1 group). Systematic RP exploration was defined as removal of nodal tissue from bilateral pelvic and para-aortic sites; selective RP exploration was defined as removal of nodal tissue from at least 1 but not all pelvic and/or para-aortic nodal sites. The no RP exploration group included patients with Original Article 2 cm of IP tumor with no RP exploration (the IP/RP? group).
Patient demographics and tumor characteristics including age, race, performance status, tumor grade, and histology were extracted from GOG databases. Information describing surgical procedures and preoperative extent of disease based on 56 anatomic locations was abstracted from GOG surgical reporting forms and diagrams and stratified into groups based on a disease score (DS) and surgical complexity score (CS), as defined previously. 26 Anatomic locations reported for nodal sampling included 10 sites: right/left para-aortic, right/left common iliac, right/left external iliac, right/left obturator, and right/eft internal iliac. Operative notes and pathology reports were also reviewed to obtain accurate descriptions of disease and surgical extent. Baseline performance status was defined according to GOG criteria as 0 for normal activity, 1 for symptomatic and fully ambulatory, and 2 for symptomatic and in bed less than 50% of the time. The reported 95% confidence intervals describe the plausible range of values for the true (unobserved) hazard ratio (HR) in the population as supported by the data.
Our primary analysis examined whether the longterm clinical outcomes in stage IIIC EOC/PPC patients with optimal residual disease depended on whether a RP exploration was performed. Outcomes for the primary analysis were PFS and OS. PFS was defined as the time (in months) from date of entry in GOG-182 to documentation of disease progression or death, whichever came first. OS was defined as the time (in months) from date of entry on GOG 182 to death from any cause. Patients who were still alive were censored for OS and PFS, respectively, at the date of last follow-up. Differences in the time to event outcomes across the groups were described using adjusted HR estimates and 95% confidence intervals.
Multivariate analysis was performed to identify relationships of RP with several factors: PFS, OS, age, and R0. Adjusted HR estimates were obtained using a multivariate proportional hazards model. The potentially confounding factors, shown to be statistically associated with the RP exploration groups and the time to event outcomes in univariate analysis, were retained in the multivariate model regardless of statistical significance. The models did not account for possible confounding from significant differences in histology because of the small number of patients in the nonserous group.
The primary multivariate results were supported by subgroup-specific Kaplan-Meier estimates of the PFS and OS distributions. Log-rank tests for the null hypotheses of no association between subgroups and OS or PFS outcomes were also provided. Differences in baseline covariates among the stage IIIC subgroups were tested using the Kruskal-Wallis or Pearson chi-square tests as appropriate.
In all cases, P < .05 was considered statistically significant. The significance level was not adjusted to control for the effects of multiple testing on the overall type I error rate. All patients signed an approved informed consent and authorization permitting release of personal health information before enrollment. All institutions required approval by their local Institutional Review Board before trial initiation. Of all 689 patients who underwent RP exploration, 158 (22.9%) patients had a systematic RP exploration performed with removal tissue at bilateral pelvic and paraaortic lymph node sites, while 531 (77.1%) patients had a selective RP exploration with removal of nodal tissue from at least one site. There were 92 (13.4%) patients with resection of nodal tissue from only 1 site, and 597 (86.6%) patients with resection of nodal tissue from more than 1 site. A total of 231 (33.5%) patients underwent resection at all 10 nodal sites, whereas 374 (54.3%) patients underwent resection of at least 6 sites. When examining the groups who underwent RP exploration, the IP/RP2 group was more likely to have 1) more lymph node sites sampled, with a median of 8 sites compared with 5 sites (P < .001) in IP/RP1; 2) a bilateral sampling performed at 84.4% versus 74.8% (P 5 .002); and 3) both pelvic and para-aortic sites sampled at 57.9% versus 41.9% (P 5 .015), respectively. These data suggest a lymph node sampling in the majority of patients in both groups rather than just resection of bulky nodes. Table 1 shows the clinical and pathologic characteristics of these patients. The groups were balanced for prognostic factors including race, BMI, performance status, histology, and tumor grade. Patients in the RP exploration group were more likely to be younger (P < .001), have ovarian cancer rather than PPC (P < .001), no ascites (P 5 .007), and no gross residual disease (P < .001). The preoperative extent of disease was more likely to be low or moderate in the RP exploration group (P < .001), and the complexity of surgical procedures was higher (P < .001). There were no significant differences in the type of adjuvant chemotherapy received or the reasons for discontinuing therapy.
In multivariate modeling, the probability of having a RP exploration at the time of surgical debulking decreased with increasing age in 10-year increments (odds ratio [OR], 0.79; 95% confidence interval [CI], 0.72-0.87; P < .001). Patients with low or moderate preoperative extent of disease were significantly more likely to have a RP exploration compared with patients with high disease burden (low: OR, 7.15; 95% CI, 2.88-17.72; P < .001; moderate: OR, 1.95; 95% CI, 1.54-2.48; P < .001). Patients who underwent more complex surgical procedures were also more likely to undergo an RP exploration (OR, 3.54; 95% CI, 2.73-4.59; P < .001). Multivariate regression revealed that RP exploration was associated with significantly improved PFS (HR, 0.85; 95% CI, 0.76-0.95; P 5 .004) and OS (HR, 0.85; 95% CI, 0.75-0.96; P 5 .009) compared with the no RP exploration group (Table 2) . In multivariable proportional hazards modeling, there was no difference in survival between patients who underwent systematic RP exploration compared with those who underwent a selective RP exploration (PFS: HR, 0.95; 95% CI, 0.74-1.23; P 5 .71; OS: HR, 1.11; 95% CI, 0.89-1.38; P 5 .37). RP exploration was associated with significantly improved PFS (18.5 vs 16.0 months in the no RP exploration group; P < .01) (Fig. 1A) . Median OS was 53.3 and 42.8 months in the RP exploration and no RP exploration groups, respectively (P < .01) (Fig. 1B) . This trend was noted in both the R0 (Fig. 2) and MGRD patients but only reached statistical significance in the latter group with longer PFS (16.8 vs 15.1 months; P 5 .0108) (Fig.  3A) and OS (44.9 vs 40.5 months; P 5 .0076) (Fig. 3B) versus no exploration. The IP/RP2 group had better PFS (22.1 vs 16.0 months; P < .01) (Fig. 4A) and OS (63.1 vs 42.8 months; P < .01) (Fig. 4B) versus the IP/RP? group. Among patients who underwent RP exploration, the IP/RP2 group had better PFS (22.1 vs 17.2 months; P < .01) (Fig. 5A) and OS (63.1 vs 45.9 months; P < .01) (Fig. 5B) versus the IP/RP 1 group, respectively.
Patients who underwent a RP exploration were more likely to obtain R0 (OR, 2.02; 95% CI, 1.54-2.65; P < .001). The effects of RP exploration and R0 at cytoreduction were independently associated with improved PFS and OS. RP exploration was significantly associated with improved PFS (HR 0.85; 95% CI, 0.76-0.95; P 5 .004) and OS (HR, 0.85; 95% CI, 0.75-0.96; P 5 .009). R0 at cytoreduction was associated with significantly improved PFS (HR, 0.73; 95% CI, 0.64-0.85; P < .001) and OS (HR, 0.74; 95% CI, 0.63-0.87; P < .001).
DISCUSSION
Among stage IIIC EOC patients who underwent optimal cytoreduction, our data were associated with a significant improvement in PFS and OS for patients who underwent a RP exploration at the time of surgical debulking compared with those who did not. For the RP exploration and no RP exploration groups, PFS was 18.5 versus 16.0 months, respectively, and OS was 53.3 versus 42.8 months, respectively. In patients with MGRD, PFS and OS were significantly improved in patients who underwent an RP exploration compared with those who did not, suggesting a survival advantage in this subgroup when a thorough surgical exploration is performed at cytoreduction. Maximal cytoreductive effort at primary debulking surgery is a significant prognostic factor in EOC, but the role of systematic lymphadenectomy in prognosis and therapy is still unclear. Chan et al 27 retrospectively examined SEER data for 13,918 women with stage III-IV EOC and found that the extent of lymphadenectomy was associated with improved survival. Panici et al 23 published the first multicenter randomized trial comparing systematic lymphadenectomy and selective resection of bulky nodes. Systematic lymphadenctomy was associated with significantly improved PFS but not OS. In an exploratory data analysis of 3 prospective randomized trials, du Bois et al 28 compared complete, incomplete, and no nodal dissection in advanced ovarian cancer debulking surgery. They concluded that lymphadenectomy may offer a survival benefit to patients with complete intraperitoneal debulking to treat advanced stage disease. These results need to be confirmed in the current prospective randomized trial AGO-LION (NCT007712218), which is comparing systematic versus no lymphadenectomy in stage IIB-IV EOC optimally debulked patients with complete intraperitoneal tumor resection, with a primary endpoint of overall survival. 29 Similarly, the results of the CAR-ACO trial (NCT0128490) are still pending, which is a randomized phase III multicenter French trial comparing complete versus bulky lymphadenectomy in stage III-IV EOC patients undergoing optimal debulking surgery. 30 The primary objective of the CARACO trial is 5-year survival without recurrence.
In the current absence of definitive randomized clinical trial data, this study represents the largest set of wellannotated data on the extent of disease and surgical effort in EOC from a large, multi-institutional trial. In contrast with previous studies, our group of patients received equivalent adjuvant treatments with similar PFS and OS across treatment arms. Because they were enrolled in a clinical trial with strictly enforced eligibility criteria, this cohort is relatively uniform compared with other studies investigating this topic. All patients were treated with modern platinum/taxane-based regimens with no statistically significant difference in prognosis across the 5 arms. These factors tend to reduce the possibility of confounding and enhance the reliability of the prognostic effects we have estimated. Inclusion of patients with removal of nodal tissue from at least 1 lymph node served as a surrogate marker for RP exploration and assessment even if systematic lymphadenectomy was not performed.
Surgical effort and tumor biology interact to affect patient outcomes. Even when surgical effort results in R0, initial disease burden is a significant prognostic indicator; this concept was demonstrated in a recent study by Horowitz et al 31 in which patients with the highest preoperative disease burden had significantly poorer PFS and OS, and this was maintained in R0 patients. RP exploration may be a proxy for a more thorough surgical effort in these patients rather than tumor biology alone driving outcomes. In a prospective single-institution trial, 100 consecutive patients with stage III and IV EOC underwent RP lymph node dissection during primary cytoreductive surgery. Lymph nodes were examined and reported to be palpably macroscopically positive before or after the RP space was opened or during the nodal dissection. Of the 66% of patients with positive lymph nodes, 92% were macroscopically positive, but only 31% were palpable before RP dissection. The authors concluded that the decision not to perform lymphadenectomy for optimally debulked patients may result in unrecognized macroscopic residual disease. 32 Our data further support a therapeutic advantage of RP exploration, particularly among patients with substantial IP disease (high DS) in which the risk of RP disease may be increased compared with patients with minimal IP disease (low DS). Our data did not demonstrate a statistical advantage for RP exploration among those patients that had otherwise achieved R0 status. Given that the PFS and OS survival curves converge with almost 200 patients in each group (RP exploration versus no RP exploration), our observations are not likely attributable to type II error.
Surgeon discretion is also a potential factor that may affect patient outcomes. It is conceivable that the surgeon has impressions or information about patient prognosis that influences the RP exploration decision based on unmeasured indicators of disease burden, vitality of the patient, and so forth. Given the small but significant survival differences and the large sample size of this study, it is possible that these survival advantages are to some degree indicative of these unmeasured factors, or the "accuracy" of the surgeon's impression, and not completely about the act of exploration.
In conclusion, there is evidence that RP exploration at the time of primary debulking surgery of patients with IP stage IIIC optimally debulked epithelial ovarian cancer is associated with a survival benefit. The multivariable analysis showed that when evaluating for clinical and surgical factors such as surgical complexity and preoperative disease burden, the PFS and OS benefit remained in the group who underwent a RP exploration. This benefit is seen particularly in patients with minimal gross residual disease of <1 cm. Therefore, even if preoperative imaging is negative for lymphadenopathy, our data suggest that when minimal or no gross residual is achieved, an RP nodal exploration should be performed based on a potential survival benefit that may be conferred by the performance of the dissection.
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